Alpine Immune Sciences Profit Margin

Alpine Immune Sciences (ALPN) currently reports a profit margin of -65.17% as of March 2024. That compares with -237.18% in the prior-year period — up 72.5% year over year. That is below the Healthcare sector average of 13.45%. Use the charts on this page to explore Alpine Immune Sciences's profit margin history and peer comparisons.

Alpine Immune Sciences's profit margin increased from -237.18% to -65.17% — a 72.5% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Alpine Immune Sciences's profit margin of -65.17% is lower than the Healthcare sector average of 13.45%. That is roughly 584.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Alpine Immune Sciences's current -65.17% should be judged against Healthcare norms (sector average: 13.45%) and against ALPN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -65.17%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.45%. From there, open related valuation or income-statement pages for Alpine Immune Sciences, and consider following ALPN for alerts when major investors trade the stock.